Sanofi

Jean-Francois Gibert

Jacques Froissant

Frank Marguet

Antoine Ravet

Christophe Pacaud

Frederic Puech

Frédéric Puech

Sylvain Cote Des Combes

Sylvain Cote-Des-Combes

Compounds corresponding to the general formula (I) wherein Rrepresents a group C-alkyl, C-cycloalkyl, C-cycloalkyl-C-alkyl, C-alkyl-C-cycloalkyl, C-cycloalkyl-C-cycloalkyl, C-alkylthio-C--alkyl, C-alkoxy-C-alkyl, hydroxy-C-alkyl, hydroxy-C-alkyl-C-cycloalkyl-C-alkyl, hydroxy-C-cycloalkyl, C-fluoroalkyl or C-fluorocycloalkyl; an optionally substituted heterocyclic group; a group C-alkyl substituted with an optionally substituted heterocyclic group; Xrepresents a group chosen from hydrogen, fluorine, chlorine and bromine atoms or a group C-alkyl, C-cycloalkyl, C-cycloalkyl-C-alkyl, C-fluoroalkyl or cyano; and Rrepresents an aryl group such as phenyl or naphthyl, optionally substituted with one or more substituents,in the form of the base or of an acid-addition salt, and the therapeutic use thereof.

3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta

Compounds corresponding to the general formula (I) 

[object Object]

Growing community of inventors

Marolles en Hurepoix, France

Jean-Francois Gibert